Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
New solvent-free micronization technology expanded at the Darmstadt site in Germany
The proposed facility is expected to be operational around January, 2027
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Subscribe To Our Newsletter & Stay Updated
